InVivo Expands Biz Development VP’s role to Include Investor Relations and Corporate Communications

Cambridge, Mass.-basd InVivo Therapeutics Holdings Corp. has expanded Christopher McNulty’s role to include investor relations and corporate communications. McNulty has been serving as vice president, business development, and will continue to lead efforts in that area.

This move is part of InVivo’s outreach strategy to existing investors, new potential institutional investors, the spinal cord injury (SCI) community, and the general public. With a strong management team in place, an on-going first-in-human clinical trial, and a streamlined strategic focus on developing effective therapies for spinal cord injury, InVivo expects to have a steady flow of news over the coming year. McNulty will lead an integrated corporate communications effort that will include investor relations, public relations, medical/scientific communications, and patient advocacy.

Before coming to InVivo, McNulty served as senior director of business development at Repligen Corporation, where his responsibilities included out-licensing programs for rare neurodegenerative diseases. Previously, he was director of corporate development at Seventh Sense Biosystems and associate director of business development and alliance management at Genzyme Corporation. McNulty has also held technical roles at Transform Pharmaceuticals and Cereon Genomics. He has an MBA from Harvard Business School, and B.S. and M.Eng degrees from Massachusetts Institute of Technology.

“Combining our investor relations, public relations, medical communications, and patient advocacy efforts into a comprehensive and synergistic corporate communications function will improve our communication efforts to all our constituents,” said CEO Mark Perrin. “We have engaged excellent partners with expertise in each of these areas to assist us in our efforts, and I look forward to our future activities.”

InVivo Therapeutics Holdings Corp. is a biomaterials and biotechnology company with a focus on treatment of spinal cord injuries.